Alumis announces data from Phase 3 Onward1, Onward23 trials of envudeucitinib

Alumis (ALMS) announced new data from its Phase 3 Onward1 and Onward2 clinical trials evaluating envudeucitinib, a next-generation, highly selective oral tyrosine kinase 2 inhibitor for moderate-to-severe plaque psoriasis. The data were presented in a late-breaking oral session at the 2026 AAD Annual Meeting. Envudeucitinib demonstrated robust skin clearance, achieving high thresholds of clinical response at Week 16 that continued to deepen through Week 24 in both trials. Psoriasis Area and Severity Index, PASI, 90 responses, which emerged as early as Week 4, were achieved by 59.9% and 53.1% of envudeucitinib patients at Week 16, increasing to 68.0% and 62.1% at Week 24. PASI 100 responses followed a similar trajectory, with 29.4% and 27.7% of envudeucitinib patients achieving complete skin clearance at Week 16, rising to 41.0% and 39.5% at Week 24.